remibrutinib
novartis
['remibrutinib']
dr. d rner presents phase 2 trial on btk inhibitor #remibrutinib in #sjogren main endpoint is change in baseline essdai (side note: who is actually doing this in clinic??) #acr22 
Rheumatologist | @ACRheum MarCom Chair | @TexMed Delegate | TexMed Leadership College????? | ???? | Views = Mine | Re-tweet ? endorsement